hongo reishi

Reishi Mushroom (Ganoderma lucidum)

Identity, Taxonomy, and Natural Source

Ganoderma lucidum, commonly referred to as reishi or lingzhi, is a macrofungus belonging to the basidiomycete group that has been consumed in traditional medicinal practices for millennia, particularly within East Asian cultures. It is a large, dark mushroom with a glossy exterior and a woody texture; the Latin word lucidus means "shiny" or "brilliant" and refers to the varnished appearance of the surface of the mushroom.

In China, this mushroom is known as lingzhi, while in Japan, members of the Ganodermataceae family are referred to as reishi or mannentake. Other names that have been assigned include the mushroom of immortality, the mushroom of spiritual potency, and spiritual plant.

In total, 290 species within the family are classified under the genus Ganoderma. The basidiocarps of this genus feature a shiny surface due to thick-walled pilocystidia within an extracellular melanin matrix. Ganoderma species are distributed worldwide and are identified based on traits like the shape and color (red, black, blue/green, white, yellow, and purple) of the fruiting body, host specificity, and geographic origin.

A notable taxonomic complication has emerged from molecular research. Isolates used in medicinal studies and the commercially cultivated strains are generally named Ganoderma lucidum. However, a DNA-based investigation of retail reishi products found that many manufactured products marketed as "reishi" were identified as Ganoderma lingzhi rather than G. lucidum sensu stricto, highlighting real-world mislabeling risk.

The fungus is native to various regions in Asia, including China, Japan, Korea, and other parts of East Asia. As lingzhi mushrooms are scarce in nature, they are artificially cultivated to meet the increasing demands of international markets, with good prospects for growing Ganoderma in regions such as Vietnam due to available agro-industrial resources. Commercial cultivation uses wood logs or sawdust as a substrate. G. lucidum is rarely collected from nature and is mostly cultivated on wood logs and sawdust in plastic bags or bottles to meet the demands of international markets.

Supplements are derived from three distinct biological parts of the fungus, each with different phytochemical profiles. The active ingredients of G. lucidum differ across growth stages: most of the triterpenoids are mainly detected in the fruiting body, certain polysaccharides are increased in the mycelium, and alkaloids are increased in the spore powder. Furthermore, the extracts of the fruiting body contain more triterpenoids than those of spores.

Traditional and Historical Use

China

Ganoderma mushrooms have been used in traditional Chinese medicine (TCM) for more than 2,000 years. In the Pharmacopoeia of the People's Republic of China, the mushroom is reported to have been used for over two millennia. Use of reishi mushrooms can be traced back to ancient China, where they were first documented in texts as early as the Han Dynasty (206 BCE to 220 CE).

Traditional preparations from reishi were used to enhance stamina, immunity, and to treat inflammatory diseases such as arthritis, asthma, bronchitis, hepatitis, and nephritis, and were also used for the treatment of various cancers. In traditional Chinese medicine, reishi mushrooms are classified in a group of herbs known as Fu Zheng, which Chinese herbalists believe are the most powerful herbs for all-around strength, health, and longevity.

Traditional Chinese Medicine (TCM) practitioners prescribe lingzhi to influence the heart, lungs, liver, and kidney channels, balance Qi (the body's life force), calm the mind and relieve cough and asthma. In Chinese herbal medicine, reishi mushroom translates as "spiritual mushroom" and is traditionally used to "calm the shen." In TCM, shen refers to the mental, emotional and spiritual state of a person; when there are disharmonies within the shen, it can result in mood imbalances, and in Chinese medicine, reishi has traditionally been used to calm disturbed shen, making it helpful for nervousness and sleeplessness.

Reishi mushrooms were valued by Taoist monks for both their properties of increasing health and aiding the development of spiritual experiences and understanding. Reishi mushrooms have been rare and expensive for most of their history because they are difficult to cultivate and find in the wild. Reishi mushrooms are included in China's State Pharmacopoeia of the People's Republic of China (2000) and are touted to balance Qi, ease the mind, and support respiratory health.

Japan and Korea

In Japanese, reishi is called mannentake. This mushroom has been an integral part of Japanese traditional medicine, known as Kampo. Use in Japan paralleled Chinese traditions, with the mushroom prized for promoting health and longevity.

Traditional Preparations

Reishi mushrooms can be prepared and consumed in various forms in Chinese medicine, including decoctions (boiled extracts), powders, tinctures, and capsules, and are often used in combination with other herbs to create customized herbal formulas tailored to individual needs. Reishi tea or decoction—prepared by boiling dried reishi slices in water for one to two hours—is the most traditional preparation method and primarily extracts water-soluble compounds (polysaccharides and beta-glucans). Tinctures involve reishi soaked in alcohol (typically rice wine in traditional preparations) to extract triterpenes, which are less water-soluble.

Key Constituents and Active Compounds

Research on the therapeutic potential of reishi indicates that the basidiocarp, mycelia, and spores of reishi contain around 400 different bioactive compounds, among which triterpenoids and polysaccharides are the two major active anti-cancer constituents.

Diverse bioactive components include polysaccharides, triterpenoids, phenolic compounds, fatty acids, peptides and proteins, vitamins, minerals, and sterols. Diverse groups of chemical compounds with pharmacological activities, isolated from the mycelia and fruiting bodies of G. lucidum, include triterpenoids, polysaccharides (β-D-glucans), proteins, amino acids, nucleosides, alkaloids, steroids, lactones, lectins, fatty acids, and enzymes.

Polysaccharides (β-Glucans)

The most pharmacologically significant polysaccharide is 1,3-beta-D-glucan, a specific type of beta-glucan. Beta-glucans are complex carbohydrates composed of sugar molecules and are thought to be responsible for many of reishi's potential immune-modulating and anti-inflammatory effects.

β-Glucans modulate both innate and adaptive immunity through Toll-like receptor signaling pathways, enhancing macrophage, NK cell, and T-cell responses. More specifically, in vitro studies have demonstrated that β-glucans are powerful immunomodulators that function through surface receptors such as dectin-1, complement receptor 3 (CR3), or toll-like receptors; this recognition translates into intracellular signaling, subsequently orchestrating immune responses.

Polysaccharides such as β-1,3- and β-1,6-glucans enhance macrophage activation, stimulate interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) production, and potentiate natural killer (NK) cell cytotoxicity.

Triterpenoids (Ganoderic Acids)

Liquid chromatography-mass spectrometry and high-performance liquid chromatography analysis have identified a diverse range of compounds including ganoderic acids, lucidenic acids, ganolucidic acids, and ganoderenic acids, which are characteristic triterpenoids to the genus Ganoderma, as well as some polyphenols and flavonoids.

Ganoderic acids, a subclass of lanostane-type triterpenoids, exert significant pharmacological actions such as inhibition of histamine release, protection against liver injury, and suppression of tumor angiogenesis. Triterpenoids are recognized for their anti-inflammatory, anti-tumor, and cytotoxic activities, inhibiting tumor invasion and metastasis.

G. lucidum is the only known source of a particular group of triterpenes, also known as ganoderic acids, which have been found to have direct cancer cell cytotoxicity on a wide variety of cancer cell lines and many of them have been suggested to counter angiogenesis and metastasis.

Other Noteworthy Constituents

Reishi also contains sterols, coumarin, and mannitol. Additional phytochemicals include coumarin, mannitol, alkaloids, ganoderol, ganoderenic acid, ganoderiol, ganodermanontriol, lucidadiol, and ganodermadiol. Water- and fat-soluble vitamins have also been detected, as well as proteins and carbohydrates contributing to the overall nutritional value of the mushroom.

Established Mechanisms of Action

Immunomodulation

Reishi mushroom extract acts as a biological response modifier by targeting multiple components of the immune system. Findings indicate that reishi induces natural killer (NK) cell cytotoxicity against various cancer cell lines via activation of the natural cytotoxic receptors (NKG2D/NCR) and mitogen-activated protein kinase (MAPK)-signaling pathways, which result in exocytosis of perforin and granulysin. Reishi polysaccharides were shown to increase expression of the major histocompatibility (MHC) class I and costimulatory molecules on melanoma cells, resulting in enhanced antitumor cytotoxicity.

Anti-Inflammatory Activity

The ethanol extract of the fruiting bodies attenuated LPS-stimulated PGE2, NO, TNF-α and IL-1β production along with transcriptional suppression of COX-2, iNOS, TNF-α and IL-1β in BV2 microglia in a dose-dependent manner.

Anticancer Mechanisms

Triterpene compounds may inhibit tumor invasion by reducing matrix metalloproteinase expression, and tumor metastases by limiting attachment to endothelial cells. In breast and prostate cancer cells, polysaccharide fractions downregulate estrogen and androgen receptor expression, inhibiting hormone-responsive tumor growth. In ovarian cancer cells, reishi induced G2/M phase cell cycle arrest, activated caspase 3 to induce apoptosis, increased p53, and inhibited Akt expression.

Antimicrobial Activity

The polysaccharides, triterpenoids, proteins, and phenolic compounds in Ganoderma exhibit strong antimicrobial effects by targeting bacterial cell walls, disrupting membrane integrity, and inhibiting key microbial enzymes, and are effective against a wide range of bacteria including Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and various fungi.

Scientific Evidence by Area of Use

An important overarching caveat applies to all sections below: the pharmacological potential of reishi has been observed across areas including diabetes, inflammation, epilepsy, neurodegeneration, cancer, anxiety, sedation, cardiac diseases, depression, hepatic diseases, and immune disorders; however, most of the studies are preclinical with a number of drawbacks, and quality clinical data are intensely needed to support pharmacological activities for human use.

Immune Function

Human/clinical evidence (moderate): A randomized, double-blinded, placebo-controlled clinical trial was conducted among healthy adult volunteers aged 18 to 55. Participants self-administered the interventions or placebos on a daily basis for 84 days, with bloodwork assessments at the beginning and end of the study. The results showed that subjects in the intervention group, who received reishi β-glucan, exhibited a significant enhancement in various immune cell populations, including CD3+, CD4+, CD8+ T-lymphocytes, as well as an improvement in the CD4/CD8 ratio and natural killer cell counts compared to the placebo group.

There is preliminary research suggesting that reishi could potentially have immune-modulating effects in healthy adults; however, rigorous trials are needed in the cancer population.

Cancer (as Adjunct Therapy)

Human/clinical evidence (weak to limited): The latest laboratory research and preclinical trials of G. lucidum have shown promising results of its antitumor activity; however, clinical evidence of its efficacy is sparse.

In an open-label trial done in China, 36 patients with advanced lung cancer were given an over-the-counter product made from reishi called Ganopoly. The patients were being treated with chemotherapy or radiation therapy, along with other complementary therapies. Some patients had marked changes in immune responses being studied, such as lymphocyte count and natural killer cell activity, and some patients had no change in immune response.

A 2011 systematic review and meta-analysis evaluated the effects of G. lucidum, regardless of preparation, in Chinese cancer patients. A total of five randomized controlled trials met inclusion criteria, all of which had unsatisfactory methodological quality. The analysis showed a positive treatment response was more likely to occur in patients who received G. lucidum in combination with chemo-/radiotherapy than with either G. lucidum or chemo-/radiotherapy alone. The data are insufficient to justify use of G. lucidum as a first-line treatment for cancer.

A Cochrane systematic review of reishi for cancer treatment concluded that the evidence from the studies was of low to very low quality. Quality was lower because most studies did not clearly describe how people were randomised or allocated to treatment, and there were few or very few people in the studies. In some cases, the results from individual studies were also inconsistent. Based on the evidence to date, using Ganoderma lucidum for cancer treatment may increase the chance of better response to treatment, but this is uncertain.

A pilot randomized trial of non-small cell lung cancer patients on chemotherapy did not find significant differences in quality of life relative to placebo, although reishi appears to be safe and have minimal toxicity.

Fatigue and Neurasthenia

Human/clinical evidence (moderate for specific population): A randomized, double-blind, placebo-controlled study published in the Journal of Medicinal Food enrolled 132 patients diagnosed with neurasthenia (a condition characterized by chronic fatigue, weakness, poor sleep, and irritability). Participants received a standardized reishi polysaccharide extract or placebo for 8 weeks. The reishi group showed significantly greater improvement in fatigue scores compared to placebo by week 8; sense of well-being improved more in the reishi group than placebo; and effects were noticeable by week 4 but became statistically significant by week 8, suggesting reishi requires sustained use. This is considered one of the better-designed reishi trials to date. However, the fatigue RCT was conducted in neurasthenia and may not map perfectly to everyday stress.

Cardiovascular Risk Factors and Metabolic Syndrome

Human/clinical evidence (weak to null): Several small studies suggest Ganoderma lucidum is well tolerated and might improve multiple cardiovascular risk factors including blood pressure, blood glucose, triglycerides and cholesterol profiles. However, when subjected to rigorous testing, these effects have not been confirmed. A randomized, multi-blind, placebo-controlled clinical trial enrolled 84 adults with metabolic syndrome and high fasting blood glucose to investigate the safety and efficacy of 3 g/day G. lucidum (with and without Cordyceps sinensis) on hyperglycemia and cardiovascular risk factors. Compared to placebo, none of the primary (HbA1c, fasting plasma glucose) or secondary outcomes (i.e., lipid parameters, blood pressure, anthropomorphic measurements) were significantly affected by the interventions after 16 weeks.

Randomized controlled trials do not support the use of reishi for reducing cardiovascular risk factors associated with type 2 diabetes.

Blood Glucose (Diabetes)

Human/clinical evidence (mixed, preliminary): In vitro and diabetic rodent studies suggest that Ganoderma lucidum can improve blood glucose and serum insulin levels, whilst protecting pancreatic islets from free radical damage. However, as noted above, the most rigorous human RCT in type 2 diabetes found no meaningful improvements in glycemia. In a review, Ganopoly 1,800 mg three times daily reduced postprandial glucose values in patients with type 2 diabetes in a clinical trial—though this result has not been consistently replicated in larger, better-controlled studies.

Urinary Tract Symptoms

Human/clinical evidence (preliminary): Clinical studies indicate benefits of reishi in improving lower urinary tract symptoms (LUTS) in men. These findings are based on small trials and require replication in larger studies before firm conclusions can be drawn.

Anxiety and Mood

Human/clinical evidence (very limited): Clinical studies indicate reishi may have a role in lowering anxiety. A double-blind, randomized placebo pilot trial was carried out, with one group taking 6 g/day of micro-milled G. lucidum carpophores for 6 weeks, during which the second group took a placebo. Results did not show any statistically significant between-group differences, although a distinct trend of improved levels of happiness and satisfaction with life and reduced depression were evident at the end.

Fibromyalgia

Human/clinical evidence (negative): Reishi did not influence blood or anthropometric measurements in patients with fibromyalgia.

Alzheimer's Disease

Human/clinical evidence (negative, pilot only): A pilot study of reishi spore powder did not find it helpful in treating patients with Alzheimer's disease.

Gulf War Illness

Human/clinical evidence (very limited, mixed): A placebo-controlled, pseudo-randomized, crossover design was used to test the effects of reishi mushroom in 29 men with Gulf War Illness (GWI). Participants completed 30 days of symptom reports for baseline, then placebo, followed by lower-dose and higher-dose botanical. GWI symptom severity was unchanged from placebo in the reishi lower-dose condition, and was higher in the higher-dose condition; reishi may exaggerate symptoms in some GWI sufferers. These results are in a small sample and are preliminary.

Hepatoprotective Effects

Evidence (preclinical; contradicted by clinical hepatotoxicity reports): Reviews of hepatoprotective activity have focused largely on in vivo studies of Ganoderma lucidum effects in animal models of hepatotoxicity, suggesting that the polysaccharides and triterpenoids are the active principles, while stressing the need for clinical trials in humans with acute liver failure. Human data on hepatoprotective benefit are not established, while paradoxically there are documented clinical case reports of hepatotoxicity (see Safety section).

Body Systems and Health Areas of Association

• Immune system: Immunomodulation via β-glucans, NK cells, T-cells, macrophage activation
• Oncology (adjunct): Antitumor mechanisms in vitro; limited adjunct role in clinical studies
• Cardiovascular system: Studied for blood pressure, lipid profiles, and cardioprotective effects; RCT evidence is not supportive
• Metabolic/endocrine: Blood glucose regulation studied in diabetes; RCT evidence is not supportive
• Liver: Hepatoprotective properties in preclinical models; rare hepatotoxicity in humans
• Nervous system / mood: Traditional use for calming shen; preliminary evidence for fatigue reduction in neurasthenia; very limited data on anxiety and mood
• Urinary tract: Some clinical evidence for improvement in lower urinary tract symptoms in men
• Respiratory system: Traditional use for asthma and cough; no robust clinical trial evidence
• Antimicrobial: In vitro activity against bacteria and fungi; clinical evidence absent

Dosage Forms and Dosages Reported in Studies

Reishi supplements are available as dried mushroom powder (ground whole fruiting body, sometimes including mycelium), which contains the full spectrum of compounds at lower concentrations than extracts. Other preparations include tea or decoction (dried reishi slices boiled in water for one to two hours, which primarily extracts water-soluble polysaccharides), and tinctures (reishi soaked in alcohol to extract triterpenes).

Reishi mushroom has most often been used by adults in doses of 1,400–5,400 mg by mouth daily, usually in divided doses; extracts have also been used in lower doses.

The Pharmacopoeia of the People's Republic of China recommends 6 to 12 g reishi extract daily. Ganopoly (a Ganoderma lucidum polysaccharide extract) in doses up to 5.4 g daily (equivalent to 81 g of the fruiting body) for 12 weeks has been used in a few clinical trials.

Specific dosages documented in key clinical trials include:

• The standard daily dose for a basic extract (essentially dehydrated mushroom powder) ranges from 1.44 g to 5.2 g, with 5.2 g split across three doses being the most widely used amount in clinical research.
• A trial of 132 patients with chronic fatigue used 1,800 mg of a polysaccharide extract three times daily for eight weeks and found improvements in wellness and fatigue scores compared to placebo, with no signs of liver, kidney, or blood-related toxicity.
• A randomized placebo-controlled clinical trial enrolled 84 adults with metabolic syndrome and used 3 g/day of G. lucidum.
• A double-blind, randomized placebo pilot trial used 6 g/day of micro-milled G. lucidum carpophores for 6 weeks.
• A 2025 GRADE-assessed systematic review and meta-analysis found that studies have used Ganoderma lucidum supplementation at doses ranging from 200 mg to 11,200 mg per day for durations of 1–24 weeks.

Mushrooms in general tend to be approximately 90% water, which makes a basic mushroom extract dehydrated mushroom powder; thus, 1 g extract, if unspecified, may be about as potent as 10 g of the raw mushroom.

The phytochemical makeup of products varies considerably by part used and extraction method. The triterpenoids with medicinal values are almost non-existent in liquid culture (mycelium fermentation). Beta-glucans (polysaccharides) are water-soluble and primarily support immune function, while triterpenes (ganoderic acids) are alcohol-soluble and are associated with reishi's calming, anti-inflammatory, and potential cognitive benefits.

Safety Considerations and Drug Interactions

General Tolerability

G. lucidum was generally well tolerated by most participants in clinical trials with only a scattered number of minor adverse events. No major toxicity was observed across the studies. Although there were few reports of harmful effect of G. lucidum, the use of its extract should be judicious, especially after thorough consideration of cost–benefit and patient preference.

After consumption of 1.44 g reishi extract (equivalent to 13.2 g fresh mushroom) for 28 days was not associated with any toxicological signs in blood, liver, or cardiac parameters.

Hepatotoxicity

This is the most clinically significant safety concern for reishi. Cases of liver injury from reishi have ranged in severity from minimally symptomatic elevations in serum aminotransferase levels to cases of mild hepatitis resolving rapidly upon stopping to severe hepatitis with symptoms and signs of acute liver failure. Liver injury from reishi is typically hepatocellular but self-limited in course, and chronic injury has not been described.

The National Institute of Diabetes and Digestive and Kidney Diseases rates reishi as a "possible rare cause of clinically apparent liver injury." Symptoms typically appear one to two months after starting reishi, though the range spans from a few days to six months. Warning signs include fatigue, nausea, abdominal pain, loss of appetite, dark urine, and yellowing of the skin or eyes. In most reported cases, stopping reishi led to full recovery within one to three months.

A documented case from the NIH LiverTox database involves a 78-year-old Chinese woman who had taken lingzhi for a year and then switched to a powdered formulation; she developed fatigue and dark urine one month later (bilirubin 15.8 mg/dL, ALT 306, Alk P 388 U/L, INR normal), improved slowly after stopping, and had near-normal liver tests five months later.

Although this fungus has been shown to have antioxidant and even hepatoprotective effects in some models, in certain reported cases it has been associated with hepatotoxicity. One fatal case involved a 47-year-old woman who switched from boiled reishi slices to a powdered form and developed liver failure within two months. Several of the documented cases share a detail worth noting: the person had recently switched to a new reishi product or a more concentrated powdered formulation.

The mechanism and the ingredient in reishi responsible for liver injury have not been identified. The most characteristic ingredients are polysaccharides and triterpenoids, which have been extensively studied in animals and have not been linked to liver injury.

Antiplatelet and Anticoagulant Effects

Some clinical evidence suggests that reishi may have anticoagulant properties at higher doses. A study found that doses of 3,000 mg per day had a blood-thinning effect, while lower doses (1,500 mg per day) may not. Ganoderic acids have demonstrated antiplatelet aggregation effects in laboratory studies. As it may increase bleeding time, reishi (Ganoderma lucidum) is not recommended for those taking anticoagulant (blood-thinning) medications.

Drug Interactions

Reishi mushroom may enhance the adverse/toxic effects of agents with antiplatelet properties, anticoagulants, herbs with anticoagulant/antiplatelet properties, NSAIDs, salicylates, and thrombolytic agents.

Reishi mushroom's influence on liver metabolism may include interactions with drug-metabolizing enzymes. It has been suggested that reishi compounds may modulate cytochrome P450 enzyme activity, which plays a critical role in the metabolism of many pharmaceuticals. This could potentially alter the clearance or bioavailability of co-administered medications, though human clinical evidence for this interaction is not firmly established.

Reported Adverse Events

Documented adverse effects include GI discomfort (nausea, diarrhea), well-documented in randomized controlled trials and cancer patient surveys; increased bleeding risk, pharmacologically established via in vitro antiplatelet activity and noted in institutional warnings from Memorial Sloan Kettering Cancer Center; dizziness and headache, reported in clinical settings and likely dose-dependent; and rare allergic reactions including hypersensitivity and hypereosinophilia.

Populations Requiring Special Consideration

Clinical studies regarding safety and efficacy, interactions with foods and drinks, chronic use, teratogenicity, mutagenicity, and genotoxicity are missing for reishi. Data in pregnant women, nursing mothers, children, and individuals with pre-existing liver disease are especially limited. A comprehensive review concludes that adequately powered clinical studies are needed to verify the biological activities of reishi that have been shown in laboratory and animal studies, and notes that hepatotoxicity has been reported in humans with its use.

Summary of Evidence Strength

• Immune modulation (healthy adults): Moderate — supported by at least one well-designed RCT showing enhanced T-cell and NK cell populations with beta-glucan supplementation over 84 days.
• Fatigue reduction (neurasthenia): Moderate — one well-designed RCT (n=132, 8 weeks, polysaccharide extract) with significant positive results; generalizability to other populations is uncertain.
• Cancer adjunct therapy: Weak — Cochrane review rated evidence as low to very low quality; no robust evidence for survival benefit; preclinical data are promising but not yet clinically confirmed.
• Metabolic syndrome / blood glucose / lipids: Negative in the best-quality RCT — one rigorous 16-week RCT found no meaningful improvements in any metabolic parameter.
• Urinary tract symptoms: Preliminary — small trials only.
• Mood / anxiety / fibromyalgia / Alzheimer's disease: Insufficient or negative — pilot studies show no statistically significant effects.
• Hepatoprotection: Preclinical only — animal model data; paradoxically, rare hepatotoxicity documented in humans.

References

• Ganoderma lucidum—From Ancient Remedies to Modern Applications: Chemistry, Benefits, and Safety — PMC / MDPI Antioxidants (2025)
• Ganoderma lucidum—From Ancient Remedies to Modern Applications: Chemistry, Benefits, and Safety — MDPI Antioxidants
• Unlocking Reishi's secrets: nutritional and medicinal traits of Ganoderma lucidum — PMC (2025)
• Ganoderma lucidum: Unutilized natural medicine and promising future solution to emerging diseases in Africa — Frontiers in Pharmacology (2022)
• Ganoderma lucidum (Reishi mushroom) for cancer treatment — Cochrane Database of Systematic Reviews / PMC
• A Summary of a Cochrane Review: Ganoderma lucidum (Reishi mushroom) for the treatment of cancer — PMC
• Lingzhi, Reishi — LiverTox® — NIH/NCBI Bookshelf
• Evaluation of Immune Modulation by β-1,3;1,6 D-Glucan Derived from Ganoderma lucidum in Healthy Adult Volunteers, A Randomized Controlled Trial — PMC (2023)
• Symptom improvements and adverse effects with Reishi mushroom use: A Cross-Sectional survey of cancer patients — PMC
• Ganoderma lucidum Effects on Mood and Health-Related Quality of Life in Women with Fibromyalgia — PMC
• A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Reishi Mushroom — PMC
• A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome — Scientific Reports (2016)
• Medicinal Mushrooms (PDQ®) — PDQ Cancer Information Summaries — NIH/NCBI Bookshelf
• Reishi Mushroom — Memorial Sloan Kettering Cancer Center Integrative Medicine
• Ganoderma lingzhi (Reishi Mushroom)-Induced Acute Liver Injury in the Setting of Alcohol Use: A Case Report and Review of the Literature — PMC (2023)
• The Species Identity of the Widely Cultivated Ganoderma, 'G. lucidum' (Ling-zhi), in China — PMC
• Ganoderma lucidum (Reishi): a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties — PubMed
• Exploring the health benefits of Ganoderma: antimicrobial properties and mechanisms of action — PMC (2025)
• A review of Ganoderma lucidum: Cultivation, active ingredients and its application as functional ingredients — ScienceDirect (2025)
• Research Breakdown on Reishi — Examine.com
• Reishi Mushroom Uses, Benefits & Dosage — Drugs.com Natural Products
• S5504 Reishi Mushroom Toxicity in Chronic Liver Disease — American College of Gastroenterology (2025)
• Patients' Expectations and Barriers Toward Reishi Mushroom Use in Cancer Care: A Cross-Sectional Survey — PMC